Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 2 mg | In stock | $ 113 | |
| 4 mg | In stock | $ 203 | |
| 8 mg | In stock | $ 268 | |
| 20 mg | In stock | $ 577 | |
| 40 mg | In stock | $ 877 |
| Description | Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). |
| Targets&IC50 | Aurora A:171 nM (ki), Aurora B:436.76 nM (ki), PLK4 G95L:68.57 nM (ki), PLK4:0.16 nM (ki) |
| In vitro | Centrinone (LCR-263) treatment causes centrosome depletion in human and other vertebrate cells and it treatment reduces centriole number in multiciliated Xenopus epithelial cells, which indicates that Plk4 also controls centriole amplification in differentiated cells. Centrinone (LCR-263) treatment of HeLa human cervical carcinoma cells leads to a progressive reduction in foci containing centriolar and pericentriolar material markers at each round of cell division, until most cells lack centrioles and centrosomes. Centrosome loss irreversibly arrests normal cells in a senescence-like G1 state by a p53-dependent mechanism that is independent of DNA damage, stress, Hippo signaling, extends mitotic duration, or segregation errors. |
| Synonyms | LCR-263 |
| CAS No. | 1798871-30-3 |
| Chemical Formula | C26H25F2N7O6S2 |
| Molecular Weight | 633.65 |
| Solubility | DMSO: 31 mg/mL (48.92 mM) |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
